Clinverse, Inc. announced that Chelsea Therapeutics has implemented ClinPay to automate investigator payments for a complex, global trial. The trial, known as Study 401, is a multi-center study of the investigational drug NORTHERA™ (droxidopa), an orally active synthetic precursor of norepinephrine, being studied for the treatment of symptomatic neurogenic orthostatic hypotension (nOH). Chelsea chose to implement ClinPay for its global study to automate the entire investigator payment process. The company recently announced that it has begun dosing patients and will be screening up to 500 patients across 100 sites throughout the U.S., Canada, and Europe.
You can read the full release here.